Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

B1532

Sigma-Aldrich

Resorufin benzyl ether

CYP450 substrate, ≥98% (TLC), powder

Sinonimo/i:

7-Benzyloxy-3H-phenoxazin-3-one, 7-Benzyloxyresorufin, O7-Benzylresorufin

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C19H13NO3
Numero CAS:
87687-02-3
Peso molecolare:
303.31
Numero MDL:
MFCD00171613
Codice UNSPSC:
12352204
ID PubChem:
24891597
NACRES:
NA.32

Nome del prodotto

Resorufin benzyl ether, CYP450 substrate

Livello qualitativo

200

Saggio

≥98% (TLC)

Stato

powder

Solubilità

chloroform: 9.80-10.20 mg/mL, clear, orange

Temperatura di conservazione

2-8°C

Stringa SMILE

O=C1C=CC2=Nc3ccc(OCc4ccccc4)cc3OC2=C1

InChI

1S/C19H13NO3/c21-14-6-8-16-18(10-14)23-19-11-15(7-9-17(19)20-16)22-12-13-4-2-1-3-5-13/h1-11H,12H2
XNZRYTITWLGTJS-UHFFFAOYSA-N

Substrati

Fluorimetric substrate for cytochrome P450-linked enzymes.

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H315,H319,H335

Classi di pericolo

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organi bersaglio

Respiratory system

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

dust mask type N95 (US), Eyeshields, Gloves

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
088M4107V
059M4095V
093M4090V
096M4080V
025M4132V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 1

1 of 1

Proadifen hydrochloride analytical standard, ≥95%

Supelco

P1061

Proadifen hydrochloride

Shosaku Kashiwada et al.
Comparative biochemistry and physiology. Toxicology & pharmacology : CBP, 141(4), 338-348 (2005-08-23)
Phylogenic analysis of the teleost genomic lineages has demonstrated the precedent for multiple genome duplications. Among many of the genes duplicated, cytochrome P450 genes have undergone independent diversification, which can be traced to a single ancestral gene. In teleosts, cytochrome
R W Nims et al.
The Journal of pharmacology and experimental therapeutics, 270(1), 348-355 (1994-07-01)
To explore further the structural requirements for ligand interaction with the putative phenobarbital receptor, the pharmacodynamics of CYP2B induction by 5,5-diphenylbarbituric acid, phenytoin (5,5-diphenylhydantoin), barbital (5,5-diethylbarbituric acid) and 5,5-diethylhydantoin were investigated in the male F344/NCr rat. Steady-state total (free plus
Lana X Garmire et al.
Pharmaceutical research, 24(12), 2171-2186 (2007-08-19)
Validate and exemplify a discrete, componentized, in silico, transwell device (ISTD) capable of mimicking the in vitro passive transport properties of compounds through cell monolayers. Verify its use for studying drug-drug interactions. We used the synthetic modeling method. Specialized software
H Y Yang et al.
Molecular pharmacology, 46(5), 922-928 (1994-11-01)
Expression of functional cytochrome P450 (CYP) isoforms in human embryonic tissues was explored during organogenesis (days 50-60 of gestation) with substrate probes, inhibitor probes, and immunoprobes and by reverse transcription-polymerase chain reaction (PCR), cloning, and sequencing. Evidence was obtained for
Y Lin et al.
Drug metabolism and disposition: the biological fate of chemicals, 29(4 Pt 1), 368-374 (2001-03-22)
Most cytochrome P450 (P450 or CYP)-catalyzed reactions are adequately described by classical Michaelis-Menten kinetic parameters (e.g., Km and Vmax), which are usually determined by a saturation profile of velocity of product formation versus substrate concentration. In turn, these parameters may
Visualizza tutti i documenti correlati

Articoli

Phase I Drug Metabolism

Phase I biotransformation reactions introduce or expose functional groups on the drug with the goal of increasing the polarity of the compound. Although Phase I drug metabolism occurs in most tissues, the primary and first pass site of metabolism occurs during hepatic circulation.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.